What is AVS?
Founded in 2017 by Dr. Hitinder Gurm and Dr. Robert Chisena, AVS is a medical technology firm dedicated to addressing the complexities of severely calcified lesions. The company's flagship innovation, the Pulse IVL system, utilizes intravascular lithotripsy to provide a safer and more effective treatment modality for patients suffering from arterial calcification. By bridging the gap between clinical expertise and engineering precision, AVS is transforming how interventional cardiologists approach high-risk vascular procedures. The firm operates at the intersection of medical innovation and patient-centric care, aiming to improve long-term outcomes in cardiovascular health through its specialized therapeutic platform.
How much funding has AVS raised?
AVS has raised a total of $64.8M across 3 funding rounds:
Series B
$20M
Series B
$8.8M
Series B
$36M
Series B (2023): $20M with participation from BioStar Capital
Series B (2023): $8.8M led by BioStar Capital
Series B (2025): $36M supported by CUE Growth Partners and BioStar Capital
Key Investors in AVS
BioStar Capital
BioStar Capital is a visionary healthcare investor focused on transformative medical devices, combining business acumen with clinical expertise to produce life-changing patient outcomes.
CUE Growth Partners
Cue Growth Partners is a New York-based growth equity firm specializing in transformational healthcare capital, providing flexible financing to accelerate clinical trials and strategic growth.
BioStar Capital
This investment arm of BioStar Capital leverages a team of renowned clinicians and financial professionals to nurture medical technologies through deep industry connections and domain expertise.
What's next for AVS?
With the successful closure of this latest funding round, AVS is poised to scale its operations and advance its clinical trial initiatives. The strategic capital will likely be deployed to enhance the manufacturing capabilities of the Pulse IVL system and support broader commercialization efforts. As the company moves forward, the focus will remain on navigating regulatory pathways and strengthening its network of clinical partnerships. By leveraging the expertise of its growth-oriented investors, AVS is set to solidify its position as a leader in the interventional therapy market, ultimately aiming to set a new benchmark for the treatment of calcified arterial disease on a global scale.
See full AVS company page
